{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:31:55Z","timestamp":1765485115528},"reference-count":23,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Faropenem was tested against 1,188 middle ear fluid pathogens from children in Israel and Costa Rica. Against\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            and\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            , faropenem was the most active \u03b2-lactam, with activity that was similar to or greater than of the other oral antimicrobial classes studied. Faropenem was also active against\n            <jats:italic>Moraxella catarrhalis<\/jats:italic>\n            and\n            <jats:italic>Streptococcus pyogenes<\/jats:italic>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.00049-07","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T01:05:02Z","timestamp":1174957502000},"page":"2230-2235","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Activity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel"],"prefix":"10.1128","volume":"51","author":[{"given":"Kimberley Clawson","family":"Stone","sequence":"first","affiliation":[{"name":"Replidyne, Inc., Louisville, Colorado 80027"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Dagan","sequence":"additional","affiliation":[{"name":"The Pediatric Infectious Disease Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Arguedas","sequence":"additional","affiliation":[{"name":"Instituto de Atencio\u0301n Pedia\u0301trica and Universidad de Ciencias Me\u0301dicas, San Jose\u0301, Costa Rica"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Leibovitz","sequence":"additional","affiliation":[{"name":"The Pediatric Infectious Disease Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Wang","sequence":"additional","affiliation":[{"name":"Replidyne, Inc., Milford, Connecticut 06460"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger M.","family":"Echols","sequence":"additional","affiliation":[{"name":"Replidyne, Inc., Milford, Connecticut 06460"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nebojsa","family":"Janjic","sequence":"additional","affiliation":[{"name":"Replidyne, Inc., Louisville, Colorado 80027"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A.","family":"Critchley","sequence":"additional","affiliation":[{"name":"Replidyne, Inc., Louisville, Colorado 80027"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506083322307"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.01.011"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000136871.51792.19"},{"key":"e_1_3_1_5_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 16th informational supplement 2006"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.550-555.2002"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2208-2218.2002"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01584355"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000070616"},{"key":"e_1_3_1_10_2","first-page":"5","volume":"11","year":"1999","unstructured":"Felmingham, D., and J. Washington. 1999. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens\u2014findings of the Alexander Project 1992-1996. J. Chemother.11(Suppl. 1):5-21.","journal-title":"J. Chemother."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.48.261"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200001000-00010"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.589"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.04.015"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1790-1797.2003"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.5.823"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806007023"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/00016480410020301"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01316-05"},{"key":"e_1_3_1_20_2","first-page":"680","volume":"51","year":"2003","unstructured":"Shimada, J., H. Takemura, K. Funahashi, and T. Kajiura. 2003. Surveillance of susceptibility of clinical isolates to various antibiotics including faropenem: antibacterial activity against aerobic bacteria isolated from common infections during 1998-2003. Jpn. J. Chemother.51:680-692.","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-002-0532-4"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.3056-3058.2005"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1693-1699.2001"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2006.05.034"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00049-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00049-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:24:58Z","timestamp":1645471498000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00049-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1128\/AAC.00049-07"],"URL":"https:\/\/doi.org\/10.1128\/aac.00049-07","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"2007-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}